A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

NCT05785624 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

286

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decided to discontinue the study after review of clinical data by the iDMC. This decision was based on unblinded evaluation of clinical efficacy which showed a trend towards futility \& was not related to any safety concerns of vixarelimab.

Conditions

Idiopathic Pulmonary Fibrosis
Systemic Sclerosis With Lung Involvement

Interventions

DRUG: Vixarelimab
DRUG: Placebo

Sponsor

Genentech, Inc.